Novavax today announced that the World Health Organization (WHO) has approved a variation to allow SK bioscience to manufacture and supply the active substance in the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine. This variation approval enables Novavax to manufacture product for countries who recognize WHO exceptional use license from two major vaccine suppliers – SK bioscience and the Serum Institute of India. This approval is the first Coalition for Epidemic Preparedness Innovations (CEPI)-funded network production for Novavax.
SK bioscience currently manufactures drug substance and drug product of Nuvaxovid for the South Korean market, drug substance for the European Union, and now, drug substance for the WHO as well.
Trade Name in the U.S.
The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.